A University of Minnesota Medical School team has received a $6 million grant to design mouse models for the study of genetic variants linked to Parkinson’s disease. “These models could help us better understand how Parkinson’s disease works and support testing of potential therapies in early stages of research,”…
News
Biogen and Denali Therapeutics have ended their clinical development of BIIB122 for people with idiopathic Parkinson’s disease after the experimental therapy failed to slow disease progression in a Phase 2b trial. The decision follows results from the Phase 2b LUMA study (NCT05348785), which compared BIIB122 (also…
A team of researchers in Germany has developed an immuno-infrared sensor (iRS) designed to detect misfolded alpha-synuclein, a protein linked to Parkinson’s disease, in body fluids including blood and the fluid that surrounds the brain and spinal cord. The researchers say the technology could one day support earlier diagnosis,…
Herantis Pharma will use a system based on smartphone technology to measure symptom changes in a Phase 2 trial testing its Parkinson’s disease treatment HER-096. Researchers will use Indivi’s digital biomarker platform alongside conventional clinical assessments to help researchers detect early changes in motor and cognitive function in…
The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease. The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage…
A pivotal clinical trial testing the light therapy device Celeste for Parkinson’s disease has wrapped up, with the last enrolled participant completing the study’s final visit. That’s according to a company press release from device developer Photopharmics, which called the completion of the…
Topline results from a Phase 2 trial testing oral bezisterim as a first-line, stand-alone treatment for early Parkinson’s disease are expected later this year following the completion of the study’s final patient visit. The developer of the therapy, Biovie, announced that researchers…
Researchers at Texas A&M University have identified a protective brain pathway — one linked to receptors responsive to nicotine but not requiring the tobacco plant chemical itself — that may be targeted to slow the progression of Parkinson’s disease. In a mouse model of Parkinson’s, boosting the number of…
Vermont has become the first U.S. state to pass legislation to ban the sale and use of paraquat, an herbicide strongly linked to an increased risk of Parkinson’s disease. With similar bills introduced in a dozen states this year — including New York, Pennsylvania, and Minnesota —…
Cellular Intelligence has acquired global rights from Novo Nordisk to STEM-PD, an allogeneic, or donor-derived, stem cell therapy program for Parkinson’s disease. Under the terms of the agreement, Cellular Intelligence will apply its artificial intelligence (AI) platform to advance the clinical development and manufacturing of the…
Recent Posts
- Bial drops Parkinson’s therapy after it fails to slow disease in trial
- How walking poles can benefit those of us with Parkinson’s disease
- New research shows Parkinson’s off episodes go beyond movement issues
- Parkinson’s therapy mirivadelgat selected for multi-drug clinical trial
- Convincing Uncle Brandon to do his exercises was an exercise itself